Calder Biosciences
Calder engineers next-gen vaccines using unique 3D-Vaxlock technology for enhanced protection against lethal viruses and pandemics.
Founded
2018Calder engineers next-gen vaccines using unique 3D-Vaxlock technology for enhanced protection against lethal viruses and pandemics.
Founded in Brooklyn, NY, Calder Biosciences is a nano-scale, molecular engineering company dedicated to developing next-generation vaccines. The company's core mission is to engineer safe, effective, durable, and tolerable vaccines that protect against some of the most challenging viral infections, including RSV and various strains of seasonal and pandemic influenza. Utilizing their unique 3D-Vaxlock technology, Calder aims to enhance immune protection against lethal viruses and pandemics, addressing the evolving nature of viral threats.
Calder Biosciences is supported by a team of experts in molecular engineering and vaccine development. Notable investors and affiliated individuals include seasoned professionals in the biotech industry, although specific names are not disclosed. Key achievements include significant advancements in vaccine technology that promise to improve public health outcomes globally. Calder’s impact lies in its potential to revolutionize how vaccines are developed, offering robust protection against some of the most intractable and life-threatening viruses.
Companies similar to Calder Biosciences include Vivaldi Biosciences, Codagenix, InvVax and Uvax Bio.
Calder Biosciences was founded in 2018.
Calder Biosciences' headquarters is located in New York City, NY, US.
Calder Biosciences' most recent funding round was for $525k (USD) in September 2023.
As of Sep 12, 2023, Calder Biosciences has disclosed funding of $8.9M (USD). Undisclosed round amounts are excluded.
Calder Biosciences has 7 employees as of Feb 4, 2024.
Uvax Bio
uvaxbio.com
